Company Profile

About Us

AdvanDx is a leading provider of rapid and accurate molecular diagnostic tests for identification of pathogens that cause critical infections in hospitalized patients. The rapid results help physicians and pharmacists optimize antibiotic therapy earlier in order to improve patient care and outcomes while limiting unnecessary antibiotic use and reducing cost.

AdvanDx is the market leader in molecular testing of positive blood cultures, enabling clinical microbiology labs to report pathogen identification results 48 to 72 hours earlier than with conventional testing methods. When used by physicians and pharmacists to ensure early,  appropriate antibiotic therapy for patients with bloodstream infections (a.k.a. septicemia), AdvanDx's PNA FISH® tests have been shown in clinical studies to reduce patient mortality, shorten length of stay (LOS) and lower hospital costs.

AdvanDx employs a Whole Cell Analysis (WCA) ap­proach to pathogen identification using our proprietary Peptide Nucleic Acid Fluorescence In Situ Hybridiza­tion (PNA FISH) technology platform. This technology enables fast and highly accurate single cell analysis for bacterial species identification in samples from patients with critical infections.

PNA FISH employs fluorescent-labeled PNA probes to target the species-specific rRNA sequences in a highly sensitive and specific assay that enables whole cell visu­alization of the target pathogen(s) using fluorescence microscopy.